PUBLICATIONS

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Nephrol Dial Transplant (2016) 31: 337–348

Press Release: ERA-EDTA recommendation on the use of tolvaptan in polycystic kidney disease
9 February 2016

Spithoven EM, Kramer A, Meijer E, Orskov B,  Wanner C, Abad JM, Aresté N, Alonso de la Torre R, Caskey F, Couchoud C, Finne  P, Heaf J, Hoitsma A, de Meester J, Pascual J, Postorino M, Ravani P, Zurriaga  O, Jager KJ, Gansevoort RT; ERA-EDTA Registry; EuroCYST Consortium; WGIKD;  ERA-EDTA Registry. Renal replacement therapy for autosomal  dominant polycystic kidney disease (ADPKD) in Europe: prevalence and  survival-an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv15-iv25. PubMed

  
Petzold K, Gansevoort RT, Ong AC, Devuyst O, Rotar L, Eckardt KU,  Köttgen A, Pirson Y, Remuzzi G, Sandford R, Tesar V, Ecder T, Chaveau D, Torra  R, Budde K, Le Meur Y, Wüthrich RP, Serra AL. Building a network of ADPKD reference centres  across Europe: the EuroCYST initiative.  Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv26-iv32. PubMed
 

Emma F, Nesterova G, Langman C, Labbé A,  Cherqui S, Goodyer P, Janssen MC, Greco M, Topaloglu R, Elenberg E, Dohil R,  Trauner D, Antignac C, Cochat P, Kaskel F, Servais A, Wühl E, Niaudet P, Van't  Hoff W, Gahl W, Levtchenko E. Nephropathic cystinosis: an international  consensus document.  Nephrol Dial Transplant. 2014 Sep;29(suppl 4):iv87-iv94.  Review. PubMed
  

Ars E, Bernis C, Fraga G, Martínez V,  Martins J, Ortiz A, Rodríguez-Pérez JC, Sans L, Torra R; on behalf of the  Spanish Working Group on Inherited Kidney Disease. Spanish guidelines for the management of  autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014 Sep;29(suppl 4):iv95-iv105.  Review. PubMed
 

Devuyst O, Knoers NV, Remuzzi G, Schaefer F; Board of the  Working Group for Inherited Kidney Diseases of the European Renal Association  and European Dialysis and Transplant Association. (2014). Rare inherited kidney diseases: challenges,  opportunities, and perspectives. Lancet 383:1844-59 PubMed
 

Spithoven EM, Kramer A,  Meijer E, Orskov B, Wanner C, Caskey F, Collart F, Finne P, Fogarty DG,  Groothoff JW, Hoitsma A, Nogier MB, Postorino M, Ravani P, Zurriaga O, Jager  KJ, Gansevoort RT; on behalf of the ERA-EDTA Registry; EuroCYST Consortium; the  WGIKD. (2014). Analysis of data from the  ERA-EDTA Registry indicates that conventional treatments for chronic kidney  disease do not reduce the need for renal replacement therapy in autosomal  dominant polycystic kidney disease. Kidney Int 2014 May 14. PMID: 24827775 [Epub ahead of print] PubMed
  

Devuyst O*, Antignac C*, Bindels RJ*, Chauveau D*, Emma F*, Gansevoort R*, Maxwell  PH*, Ong AC*, Remuzzi G*, Ronco P*, Schaefer F. * (2012) The ERA-EDTA Working Group on inherited kidney disorders. Nephrol Dial Transplant 27: 67-9 (* Equivalent senior author) PubMed